Publications
3 shownBRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with <i>BRAF</i> V600E mutation-positive metastatic melanoma.
8509 Background: Most agents tested in large phase II trials in patients (pts) with metastatic melanoma have response rates of 10-20%. Approximately 50% of melanomas harbor a V6...
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain meta...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 2,915
- Institution
- University of North Carolina at Chapel Hill
External Links
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.